stockrow
Friday 6 November 2026
Export BSX’s income statement to Excel — free account
Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.5%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
42.73
1.91
−4.28%
Follow BSX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
48.65 | 26.15 | 17.21 | 18.41 |
P/S ratio |
7.03 | 4.52 | 2.99 | 3.00 | |
P/FCF ratio |
38.59 | 26.81 | 17.31 | 18.98 | |
P/Operating CF |
103.49 | 267.75 | 42.57 | 60.34 | |
P/B ratio |
5.77 | 3.57 | 2.49 | 2.44 | |
Price to Tangible BV |
0.00 | 183.42 | 0.00 | 228.29 | |
EV/Sales |
7.50 | 4.98 | 3.56 | 3.54 | |
EV/EBITDA |
29.97 | 19.65 | 13.46 | 13.81 | |
EV/Operating CF |
33.22 | 23.67 | 16.52 | 17.61 | |
EV/FCF |
41.18 | 29.57 | 20.64 | 22.39 | |
Quick Ratio |
0.90 | 0.98 | 0.56 | 0.62 | |
Current Ratio |
1.62 | 1.90 | 1.24 | 1.36 | |
Net Debt/EBITDA |
7.97 | 6.60 | 7.88 | 9.24 | |
Debt/Assets |
26.19% | 24.87% | 27.92% | 26.29% | |
Debt/Equity |
0.47 | 0.42 | 0.50 | 0.46 | |
Asset Turnover |
0.48 | 0.49 | 0.48 | 0.48 | |
Operating CF/Net income |
2.03 | 0.26 | 1.63 | 1.80 | |
Capex/Depreciation |
(0.96) | (0.50) | (0.55) | (0.45) | |
Interest Coverage |
9.16 | 12.21 | 12.27 | 8.28 | |
Research and Development Expense of Revenue |
10.77% | 9.92% | 10.18% | 10.12% | |
Selling, General and Administrative Expense of Revenue |
34.80% | 34.46% | 33.35% | 32.99% | |
Intangible Assets out of Total Assets |
0.58 | 0.58 | 0.57 | 0.56 | |
Share Based Compensation of Revenue |
1.34% | 1.60% | 1.60% | 1.40% | |
Graham Net Nets |
(0.07) | (0.10) | (0.19) | (0.18) | |
Graham Number |
27.00 | 30.81 | 30.91 | 30.86 | |
Earnings Yield |
2.06% | 3.82% | 5.81% | 5.43% | |
Free Cash Flow Yield |
2.59% | 3.73% | 5.78% | 5.27% | |
Revenue per Share |
3.57 | 3.50 | 3.70 | 3.55 | |
Operating CF per Share |
0.92 | 0.23 | 1.00 | 0.72 | |
Capex per Share |
(0.24) | (0.12) | (0.13) | (0.12) | |
Free Cash Flow per Share |
0.68 | 0.12 | 0.87 | 0.60 | |
Cash per Share |
1.33 | 0.98 | 0.37 | 0.42 | |
Shareholders Equity per Share |
16.53 | 17.58 | 17.12 | 17.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.53 | 17.58 | 17.12 | 17.86 | |
Free Cash Flow |
1,013.00 | 171.00 | 1,279.00 | 868.00 | |
Working Capital |
3,355.00 | 4,113.00 | 1,544.00 | 2,182.00 | |
Capital Expenditures |
(351.00) | (177.00) | (195.00) | (180.00) | |
Net Current Asset Value |
(10,407.00) | (9,563.00) | (12,072.00) | (11,424.00) | |
EV/EBIT |
41.70 | 27.12 | 18.04 | 18.98 | |
Capex to Sales |
0.07 | 0.03 | 0.04 | 0.04 | |
Price to Operating Income |
39.08 | 24.59 | 15.13 | 16.09 | |
| Other line items | |||||
Average Receivables |
2,742.00 | 2,860.00 | 2,932.00 | 2,970.50 | |
Average Payables |
1,052.00 | 1,072.50 | 1,096.50 | 1,126.00 | |
Average Inventory |
2,876.50 | 2,992.00 | 3,048.00 | 3,119.00 | |
Average Assets |
41,534.00 | 42,245.50 | 43,387.50 | 44,084.00 | |
Average Common Equity |
23,237.00 | 24,274.50 | 23,912.50 | 24,752.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026